Michigan Medicine – FDA 483, Dec 14, 2018
Michigan Medicine, a producer of sterile and non-sterile drug products in Ann Arbor, MI, was inspected by the FDA and cited for multiple deficiencies in aseptic processing. Observations included inadequate disinfection of materials, poor personnel practices, facility design issues affecting material flow, and insufficient use and documentation of sporicidal agents. These issues indicate a risk of contamination in their sterile drug production.
ID · 364d1ce8-177e-4f11-ab69-64c50d6b51c0
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.